CD19 and systemic sclerosis: Given the similarities between NMOSD and SSc regarding B cell involvement, vascular damage, and autoimmunity, Uplizna® may have therapeutic potential for SSc patients, precisely in the CD19-overexpressing SSc subset (64, 79, 80).